2008
DOI: 10.1016/j.pbb.2008.05.017
|View full text |Cite
|
Sign up to set email alerts
|

Immunosuppressant calcineurin inhibitors phase shift circadian rhythms and inhibit circadian responses to light

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
16
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 11 publications
(17 citation statements)
references
References 39 publications
(46 reference statements)
1
16
0
Order By: Relevance
“…Calcineurin is known to be involved in circadian phase-shifting in mammals (Katz et al, 2008), but it is not clear whether calcineurin itself is expressed in circadian oscillations. We first examined whether the protein expression or the activity of calcineurin was under circadian control.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Calcineurin is known to be involved in circadian phase-shifting in mammals (Katz et al, 2008), but it is not clear whether calcineurin itself is expressed in circadian oscillations. We first examined whether the protein expression or the activity of calcineurin was under circadian control.…”
Section: Resultsmentioning
confidence: 99%
“…Since calcineurin is known to cause circadian phase shifting in mammals (Katz et al, 2008), it is possible that the circadian phase-dependent regulation of L-VGCCs by calcineurin could be due to phase-shifting, in which L-VGCCα1 subunit mRNA would be affected after calcineurin inhibitor treatments. However, we found that while FK-506 dampened the circadian rhythm of L-VGCCα1D protein expression (Fig.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Interestingly, we found that a number of cyclophilins that are active on the BMAL1 TAD are also expressed in vivo on a circadian timescale, suggesting the possibility for modes of feedback regulation that are common in circadian rhythms (Baggs et al, 2009). These findings are strengthened by the observation that animals with chronic administration of peptidyl-prolyl isomerases inhibitors exhibit defects in circadian cycling (Katz et al, 2008), as do organ transplant patients on long-term dosing of CsA (Kooman et al, 2001; van de Borne et al, 1993; van den Dorpel et al, 1996). More work is needed to parse out the potentially redundant roles of cyclophilins and possibly other proline isomerases on the BMAL1 TAD.…”
Section: Discussionmentioning
confidence: 97%